PDCD1 and B-cell non-Hodgkin lymphoma: Therefore, intratumoral administration of TLR4 agonist (G100) has been shown to enhance the efficacy of systemic administration of anti-PD1 monoclonal antibodies in the A20 B cell lymphoma model[11].